Skip to Content

Mouhammed Amir Habra, M.D., F.A.C.P., F.A.C.E.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests


1. Clinical and molecular studies of benign and malignant adrenal tumors including adrenocortical carcinoma, adrenal adenomas, and pheochromocytoma

2. New treatments of endocrine malignancies including thyroid carcinoma and adrenocortical carcinoma

3. Novel markers and therapeutic targets in adrenal tumors

Education & Training

Degree-Granting Education

1995 Aleppo University, Aleppo, Syria, MD, Faculty of Medicine

Postgraduate Training

7/2002-6/2005 Clinical Fellowship, Diabetes and Metabolism, Joint Fellowship, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, Houston, TX
7/1999-6/2002 Clinical Residency, Internal Medicine, University of Missouri, Columbia, MO
12/1995-12/1998 Clinical Residency, Internal Medicine, Aleppo University Hospital, Aleppo, Syria

Board Certifications

2002 American Board of Internal Medicine, Recertification Date: 4/2012
2004 American Board, Endocrinology, Diabetes and Metabolism


Academic Appointments

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2008-9/2014

Selected Publications

Peer-Reviewed Original Research Articles

1. Takeuchi S, Balachandran A, Habra MA, Phan AT, Bassett RL Jr, Macapinlac HA, Chuang HH. Impact of (18)F-FDG PET/CT on the management of adrenocorticol carcinoma: analysis of 106 patients. Eur J Nucl Med Mol Imaging 41(11):2066-73, 11/2014. PMID: 24990404.
2. Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arti-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111-22, 9/2014. PMID: 24891137.
3. Dadu R, Waguespack SG, Sherman SI, Hu Mi, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients with Differentiated Thyroid Cancer. Oncologist. e-Pub 4/2014.
4. Bednarski BK, Habra MA, Phan A, Wood C, Vauthey JN, Evans DB, Katz MH, Ng CS, Perrier ND, Lee JE, Grubbs EG. Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role For Preoperative Chemotherapy. World Journal of Surgery. e-Pub 3/2014.
5. Shawa H, Elsayes KM, Javadi S, Sircar K, Jimenez C, Habra MA. Clinical and radiological features of pheochromocytoma/ganglioneuroma composite tumors: A case series with comparative analysis. Endocrine Practice. e-Pub 3/2014.
6. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote G, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. The Journal of Clinical Endocrinology and Metabolism. e-Pub 3/2014.
7. Cooper AB, Habra MA, Grubbs EG, Bednarski BK, Ying AK, Perrier ND, Lee JE, Aloia TA. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surg Endosc. e-Pub 6/2013. PMID: 23765427.
8. Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C. Bone Metastases and Skeletal Related Events in Patients with Malignant Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 98(4):1492-7, 4/2013. e-Pub 2/2013. PMID: 23436918.
9. Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA, Kurzrock R. Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Metastatic Adrenocortical Carcinoma. Br J Cancer 108(4):826-30, 3/2013. e-Pub 2/2013. PMCID: PMC3590681.
10. Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C, Perrier ND, Lee JE, Vassilopoulou-Sellin R. A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. J Clinical Endocrinology Metabolism 98(1):192-197, 1/2013.
11. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 1/2013. e-Pub 11/2012. PMCID: PMC3537108.
12. Ejaz S, Shawa H, Henderson SA, Habra MA. Melanoma of unknown primary origin presenting as a rapidly enlarging adrenal mass. BMJ Case Rep 2013, 2013. e-Pub 6/2013. PMID: 23784764.
13. Shawa H, Busaidy NL, Schellingerhout D, Habra MA. Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. BMJ Case Rep 2013, 2013. e-Pub 5/2013. PMID: 23682094.
14. Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J Clin Endocrinol Metab 97(11):4040-50, 11/2012. e-Pub 9/2012. PMID: 22965939.
15. Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA. [¹ F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case. J Clin Oncol 30(26):e246-9, 9/2012. e-Pub 5/2012. PMCID: PMC3434990.
16. Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 118(11):2804-12, 6/2012. e-Pub 10/2011. PMID: 22006217.
17. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer 117(19):4381-9, 10/2011. e-Pub 3/2011. PMCID: PMC3134535.
18. Khan MI, Habra MA, McCutcheon IE, Nogueras-González GM, Devin JK, Busaidy NL, Levine NB, Lindstrom W, Kagan D, Jimenez C, Waguespack SG. Random postoperative day-3 cortisol concentration as a predictor of hypothalamic-pituitary-adrenal axis integrity after transsphenoidal surgery. Endocr Pract 17(5):717-26, Sep-Oct, 9/2011. PMID: 21454228.
19. Khan MI, Waguespack SG, Habra MA, Broaddus R, Jimenez C. Acute-Onset Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Metastatic Endometrioid Carcinoma of the Ovaries As a Fatal Complication. J Clin Oncol 29(16):e462-4, 6/2011. e-Pub 3/2011. PMID: 21422435.
20. Shahani S, Ahmad A, Barakat FH, Chuang HH, Fowler NH, Myers JN, Stava C, Habra MA. F-18 FDG PET/CT Detecting Thyroid Plasmacytoma After the Successful Treatment of Gastric Large B-Cell Lymphoma. Clin Nucl Med 36(4):317-319, 4/2011. PMID: 21368613.
21. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. J Clin Endocrinol Metab 96(3):717-25, 3/2011. e-Pub 12/2010. PMID: 21190975.
22. Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple Endocrine Neoplasia Type 2B with a RET Proto-Oncogene A883F Mutation Displays a More Indolent Form of Medullary Thyroid Carcinoma Compared With a RET M918T Mutation. Thyroid 21(2):189-192, 2/2011. e-Pub 12/2010. PMCID: PMC3025175.
23. Ayala-Ramirez M, Habra MA, Busaidy N, Cote G, Rich T, Waguespack S, Jimenez C. A catecholamine crisis on Mount Kilimanjaro: a hypoxia effect? J Travel Med 17(6):424-6, Nov-Dec, 11/2010. PMID: 21050326.
24. Habra MA, Núñez R, Chuang H, Ayala-Ramirez M, Rich T, Kyle K, Jimenez C. Fatal hypoglycemia in malignant pheochromocytoma: direct glucose consumption as suggested by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging. Endocrine 37(1):209-212, 2/2010. e-Pub 1/2010. PMID: 20963572.
25. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA, Gagel RF, Hoff AO. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14(9):1108-14, 12/2008. PMID: 19158050.
26. Habra MA, Weaver EJ, Prewitt PV. Primary cutaneous large B-cell lymphoma of the leg and acute hypercalcemia. J Clin Oncol 25(36):5825-6, 12/2007. PMID: 18089880.
27. Thompson MA, Habra MA, Routbort MJ, Holsinger FC, Perrier ND, Waguespack SG, Rodriguez MA. Primary adrenal natural killer/T-cell nasal type lymphoma: first case report in adults. Am J Hematol 82(4):299-303, 4/2007. PMID: 17094095.
28. Habra MA, Vassilopoulou-Sellin R. Contribution of routine chest x-ray in the long-term follow-up of patients with differentiated thyroid carcinoma. Thyroid 16(3):303-6, 3/2006. PMID: 16571094.
29. Habra MA, Jimenez C, Wallace M, Evans, DB, Vassilopoulou-Sellin R. Insulinoma in a Marathon Runner Illustrating the Effects of Exercise on Insulin Sensitivity and Glucose Homeostasis. The Endocrinologist 16(1):20-24, 1/2006.
30. Picolos MK, Habra M, Safdar A, Sarlis NJ. Inactive pulmonary tuberculosis mimicking metastasis from papillary thyroid carcinoma in diagnostic radioiodine whole-body scintigraphy. Thyroid 15(9):1105-6, 9/2005. PMID: 16187924.
31. Habra MA, Vassilopoulou-Sellin R. Cervical spine metastasis mimicking thyroid bed uptake in follicular thyroid carcinoma. Thyroid 15(3):298-9, 3/2005. PMID: 15785252.
32. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716-26, 8/2004. PMID: 15287039.
33. Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of the RET Protooncogene 891 Germline Mutation. J Clin Endocrinol Metab 89(8):4142-5, 8/2004. PMID: 15292360.
34. Habra MA, Hijazi R, Verstovsek G, Marcelli M. Medullary thyroid carcinoma associated with hyperthyroidism: a case report and review of the literature. Thyroid 14(5):391-6, 5/2004. PMID: 15186618.

Invited Articles

1. Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E. Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma. Curr Oncol Rep. e-Pub 5/2013. PMID: 23674235.
2. Yeung SC, Habra MA, Thosani SN. Lung cancer-induced paraneoplastic syndromes. Curr Opin Pulm Med 17(4):260-8, 7/2011. PMID: 21577115.
3. Santarpia L, Habra MA, Jiménez C. Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies. Horm Metab Res 41(9):680-6, 9/2009. e-Pub 4/2009. PMID: 19343618.
4. Habra M, Sarlis NJ. Thyroid and aging. Rev Endocr Metab Disord 6(2):145-54, 5/2005. PMID: 15843886.


1. Hajjar J, Habra MA, Naing A. Metformin: An Old Drug with New Potential. Expert Opinion on Investigational Drugs 22(12):1511-1517, 12/2013. PMID: 23978196.


1. Schlumberger M, Tahara M, Wirth L, Robinson B, Brose M, Elisei R, Dutcus C, de las Heras B, Zhu J, Habra MA, Newbold K, Shah M, Hoff AO, Gianoukakis AG, Kiyota N, Taylor M, Kim S-B, Krzyzanowska M, Sherman SI. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). ASCO Annual Meeting 2014, 6/2014.
2. Busaidy NL, Habra MA. Metastatic Parathyroid Carcinoma and Hypercalcemia Responds to Treatment with Sorafenib. International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014:14952, 6/2014.
3. Naing A, Habra MA, Chugh R, Ijezrman M, Hesseltine E, Worden F, Phillips M, Smith D. Phase 1 study of ATR-101 in adrenocortical carcinoma (ACC): ATR-101-001. ASCO Annual Meeting 2014, 6/2014.
4. Kutahyalioglu M, Elsayes K, Vicens RA, Sircar K, Jazaerly T, Ozsari L, Jimenez C, Waguespack SG, Busaidy NL, Cabanillas ME, Grubbs EG, Habra MA. Preexisting Adrenal Masses in patients with Adrenocortical Carcinoma: Byeond Size Alone. International Society of Endocrinology and The Endocrine Society: ICE/ENDO 2014, 6/2014.
5. Phan L, Feuntes-Mattei E, Velazquez-Torres G, Wu W, Sircar K, Wood CG, Hai T, Jiemenz C, Cote G, Lee MH, Yeung SC J, <b>Habra MA</b>. Hepatocyte Growth Factor and c-Met Signaling Promotes Growth of Adrenocortical Carcinoma. MDACC Divison of Medicine Research Reterat 2014, 5/2014.
6. Fuentes-Mattei E, Phan L, Velazquez-Torres G, Wu W, SIrcar K, Wood CG, Hai T, Jimenez C, Cote G, Lee MH, Yeung SC J, Habra MA. Inhibition of HGF/cMet signaling as a therapeutic approach for adrenocortical cancer tumor progression and drug resistance. MDACC Divisoin of Medicine Research Retereat 2014, 5/2014.

Book Chapters

1. Romero MA, Habra MA, Perrier ND. Adrenal Tumors. In: UICC Manual of Clinical Oncology, 9th. John Wiley & Sons Limited. In Press.
2. Hu MI, Jimenez C, Busaidy NL, Habra MA. Long-Term and Late Endocrine Effects of Cancer Survivorship. In: Advances in Cancer Survivorship Management (MD Anderson Cancer Care Series). Springer, 2014. ISBN: 978-1493909858.
3. Flores S, Habra MA. Thyroid Cancer Survivorship. In: Advances in Cancer Survivorship Management (MD Anderson Cancer Care Series). Springer, 2014. ISBN: 978-1493909858.
4. Schultz PN, Stava CJ, Habra MA, Sellin RV. Adult Long-term Follow-up. In: M.D Anderson Manual of Medical Oncology, Second. Ed(s) Kantarjian, Wolf, and Koller. McGraw Hill: USA, 1341-1350, 2011.
5. Habra MA, Busaidy NL, Yeung J, Sellin RV. Endocrine and Metabolic Complications of Cancer Therapy. In: M.D Anderson Manual of Medical Oncology, Second. Ed(s) Kantarjian, Wolf, Koller. McGraw Hill: USA, 1235-1255, 2011.
6. Busaidy NL, Habra MA, Sellin RV. Endocrine Malignancies. In: M.D Anderson Manual of Medical Oncology, Second. Ed(s) Kantarjian, Wolf, Koller. McGraw Hill: USA, 1039-1076, 2011.
7. Haddad R, Habra MA. Cancer of Endocrine System. In: Hellman and Rosenberg's Cancer: Principles and Practice of Oncology Review, 2nd. Ed(s) R Govindan. WoltersKluwer/Lippincot Williams & Wilkins: USA, 2009.
8. Habra MA, Vassilopoulou-Sellin R, Clayman G. Parathyroid Carcinoma. In: Advanced Therapy in Surgical Oncology, 1. Ed(s) Pollock, Curley, Ross, Perrier. B. C. Decker Incorporated, 2007.
9. Amos KD, Habra MA, Perrier NC. Carcinoma of the Thyroid and Parathyroid Glands. In: The M.D. Anderson Surgical Oncology Handbook, 4th. Ed(s) Lippincott Williams & Wilkins, 2006.
10. Habra MA, Busaidy NL, Yeung SJ, Vassilopoulou-Sellin R. Endocrine Complications of Cancer Therapy. In: The MD Anderson Manual of Medical Oncology. Ed(s) McGraw-Hill, 2006.
11. Busaidy NL, Habra MA, Vassilopoulou-Sellin R. Endocrine Malignancies. In: The MD Anderson Manual of Medical Oncology. Ed(s) McGraw-Hill, 2006.
12. Habra MA. Chapter 21, In DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology Review. In: Endocrine Tumors, 1. Ed(s) Ramaswamy Govindan. Lippincott Williams & Wilkins, 2005.

Books (edited and written)

1. Habra MA, Vassilopoulou-Sellin R. M.D. Anderson Atlas of Endocrine Neoplasia, 2006.

Last updated: 2/17/2015